Latest News of GPC
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
By Yahoo! Finance |
1 week ago
The article discusses the market trends and investment strategies amidst volatility, focusing on the performance of small-cap vs. large-cap stocks. Analysts emphasize a balanced approach, with insight...
At US$143, Is It Time To Put Genuine Parts Company (NYSE:GPC) On Your Watch List?
By Yahoo! Finance |
1 month ago
Genuine Parts Company (NYSE:GPC) has shown price fluctuations, offering potential buying opportunities. With a stable share price and expected earnings growth, it may be a good investment. Investors s...
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
By Yahoo! Finance |
1 month ago
Investing in unprofitable businesses like biotech and mining exploration companies can be profitable, but risks exist. Analyzing Structure Therapeutics, its cash burn rate is low compared to cash rese...
-
Genuine Parts Company (GPC): Best Dividend Stock of All Time According to Hedge Funds?
By Yahoo! Finance | 2 months agoThe article discusses Genuine Parts Company's standing among top dividend stocks, emphasizing the long-term benefits of dividend investing. It highlights the company's dividend growth, financial stabi...
-
Decoding Genuine Parts Co (GPC): A Strategic SWOT Insight
By Yahoo! Finance | 2 months agoGenuine Parts Co (NYSE:GPC) reports a dip in net income but shows resilience with a solid comprehensive income. Strategic investments, acquisitions, financial stability, and market expansion opportuni...
-
Genuine Parts Company (GPC) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 3 months agoGenuine Parts Company distributes automotive and industrial replacement parts. It serves various sectors and provides repair services in multiple countries since 1928....
-
Genuine Parts' (NYSE:GPC) five-year total shareholder returns outpace the underlying earnings growth
By Yahoo! Finance | 3 months agoWhile Genuine Parts Company's stock has recently fallen, its long-term growth is solid. The company's EPS has outpaced its share price increase, indicating market pessimism. CEO pay is modest, and div...
-
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
By Yahoo! Finance | 3 months agoTectonic Therapeutic completes reverse merger with Avrobio, now trading on Nasdaq as Tectonic Therapeutic (TECX). The new company raised $130.7m in a private placement, ensuring cash reserves of $181m...